a therapeutically focused leader in research-based drug development, medpace builds strong strategic partnerships with select sponsors to advance the most efficient and cost-effective path to drug approval. as a full service, global clinical research organization (cro), medpace sees itself as a steward of your drug, leveraging its extensive medical and regulatory expertise to deliver additional input, strategy, and efficiencies to each and every phase of the clinical trial. from custom solutions addressing the needs of small and midsize biotechnology companies to full-service offerings for global pharmaceutical companies, medpace has the breadth, depth, and flexibility to deliver a superior result, specific to your needs, on six continents.
Company profile
Ticker
MEDP
Exchange
CEO
August Troendle
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
PPD • IQVIA • PRA Health Sciences • Charles River Laboratories International • Icon • Syneos Health • Incyte • Zymergen • OmniAb • SomaLogic ...
SEC CIK
Corporate docs
Subsidiaries
Delaware Medpace Acquisition, Inc. • Delaware Medpace IntermediateCo, Inc. • Ohio Imagepace, LLC • Ohio Medpace Clinical Pharmacology LLC • Ohio Medpace, Inc. • Ohio Medpace Reference Laboratories LLC ...
MEDP stock data
Latest filings (excl ownership)
8-K
Amendments to Articles of Incorporation or Bylaws
21 May 24
10-Q
2024 Q1
Quarterly report
23 Apr 24
8-K
Medpace Holdings, Inc. Reports First Quarter 2024 Results
22 Apr 24
DEFA14A
Additional proxy soliciting materials
3 Apr 24
DEF 14A
Definitive proxy
3 Apr 24
ARS
2023 FY
Annual report to shareholders
3 Apr 24
8-K
Entry into a Material Definitive Agreement
29 Mar 24
PRE 14A
Preliminary proxy
20 Mar 24
10-K
2023 FY
Annual report
13 Feb 24
8-K
Medpace Holdings, Inc. Reports Fourth Quarter and Full Year 2023 Results
12 Feb 24
Transcripts
MEDP
Earnings call transcript
2024 Q1
23 Apr 24
MEDP
Earnings call transcript
2023 Q4
13 Feb 24
MEDP
Earnings call transcript
2023 Q3
24 Oct 23
MEDP
Earnings call transcript
2023 Q2
25 Jul 23
MEDP
Earnings call transcript
2023 Q1
25 Apr 23
MEDP
Earnings call transcript
2022 Q4
14 Feb 23
MEDP
Earnings call transcript
2022 Q3
25 Oct 22
MEDP
Earnings call transcript
2022 Q2
26 Jul 22
MEDP
Earnings call transcript
2022 Q1
26 Apr 22
MEDP
Earnings call transcript
2021 Q4
15 Feb 22
Latest ownership filings
4
August J. Troendle
24 May 24
4
August J. Troendle
22 May 24
4
Cornelius P. McCarthy III
21 May 24
4
Ashley M. Keating
21 May 24
4
Femida H. Gwadry-Sridhar
21 May 24
4
Robert O. Kraft
21 May 24
4
Brian T Carley
21 May 24
4
FRED B DAVENPORT JR
21 May 24
4
August J. Troendle
17 May 24
4
August J. Troendle
14 May 24
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q1 2024
13F holders | Current |
---|---|
Total holders | 565 |
Opened positions | 192 |
Closed positions | 43 |
Increased positions | 140 |
Reduced positions | 177 |
13F shares | Current |
---|---|
Total value | 8.84 tn |
Total shares | 39.25 mm |
Total puts | 117.10 k |
Total calls | 154.00 k |
Total put/call ratio | 0.8 |
Largest owners | Shares | Value |
---|---|---|
Cinven Capital Management | 10.40 mm | $451.26 mm |
Troendle August J. | 4.76 mm | $1.95 bn |
Vanguard | 2.50 mm | $1.01 tn |
BLK Blackrock | 2.49 mm | $1.01 tn |
Wasatch Advisors | 974.42 k | $393.81 bn |
IVZ Invesco | 815.80 k | $329.71 bn |
STT State Street | 696.96 k | $281.68 bn |
Riverbridge Partners | 606.25 k | $245.02 bn |
TD Asset Management | 574.15 k | $232.04 bn |
Geode Capital Management | 532.75 k | $215.34 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 May 24 | Troendle August J. | Common Stock | Sell | Dispose S | No | No | 400 | 55 | 22.00 k | 664,338 |
20 May 24 | Troendle August J. | Common Stock | Sell | Dispose S | No | No | 400.19 | 4,020 | 1.61 mm | 664,393 |
17 May 24 | Davenport Fred B JR | Stock Option Common Stock | Grant | Acquire A | No | No | 393.3 | 953 | 374.81 k | 953 |
17 May 24 | Carley Brian T | Stock Option Common Stock | Grant | Acquire A | No | No | 393.3 | 953 | 374.81 k | 953 |
17 May 24 | Kraft Robert O. | Stock Option Common Stock | Grant | Acquire A | No | No | 393.3 | 953 | 374.81 k | 953 |
News
A Glimpse Into The Expert Outlook On Medpace Hldgs Through 6 Analysts
28 May 24
Mizuho Initiates Coverage On Medpace Hldgs with Buy Rating, Announces Price Target of $435
28 May 24
Haemonetics Stock Up 10.9% YTD: Will the Rally Continue?
17 May 24
Prestige Consumer Q4 Earnings Miss, Operating Margin Falls
16 May 24
Here's How Much You Would Have Made Owning Medpace Hldgs Stock In The Last 5 Years
14 May 24